Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.
Plenary Session
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
Special episode! We discuss the recent correspond…
Plenary Session
Dr Prasad on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com
Dr Prasad on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.comListen on
Appears in episode
Recent Episodes
